Protalix BioTherapeutics (PLX) Non-Current Assets (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Non-Current Assets of $16.0 million for Q1 2026, up 19.45% year-over-year from $13.4 million in Q1 2025, and up 1.96% quarter-over-quarter from $15.7 million in Q4 2025.
Protalix BioTherapeutics (PLX) Non-Current Assets (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $16.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 19.45% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $60.4 million (up 10.65% YoY), while the FY2025 annual figure was $15.7 million, up 17.5% from the prior year.
- Non-Current Assets for Q1 2026 stood at $16.0 million, up from $15.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $16.0 million in Q1 2026, with the low at $10.9 million in Q4 2022.
- The 5-year median for Non-Current Assets is $13.7 million (2024), against an average of $13.5 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets dropped 10.92% in 2022, then jumped 36.55% in 2023.
- Protalix BioTherapeutics' Non-Current Assets stood at $10.9 million in 2022, then soared by 32.96% to $14.5 million in 2023, then dropped by 8.02% to $13.3 million in 2024, then rose by 17.5% to $15.7 million in 2025, then climbed by 1.96% to $16.0 million in 2026.
- Business Quant data shows PLX's Non-Current Assets at $16.0 million in Q1 2026, $15.7 million in Q4 2025, and $15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 18.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.12 Mn |
| Mar 31, 2026 | 15.98 Mn |
| Dec 31, 2025 | 15.67 Mn |
| Sep 30, 2025 | 15.76 Mn |
| Jun 30, 2025 | 13.00 Mn |
| Mar 31, 2025 | 13.38 Mn |
| Dec 31, 2024 | 13.34 Mn |
| Sep 30, 2024 | 13.71 Mn |
| Jun 30, 2024 | 14.17 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 14.50 Mn |
| Sep 30, 2023 | 14.95 Mn |
| Jun 30, 2023 | 14.84 Mn |
| Mar 31, 2023 | 11.16 Mn |
| Dec 31, 2022 | 10.91 Mn |
| Sep 30, 2022 | 10.95 Mn |
| Jun 30, 2022 | 10.94 Mn |
| Mar 31, 2022 | 11.85 Mn |
| Dec 31, 2021 | 12.00 Mn |
| Sep 30, 2021 | 12.26 Mn |